期刊
EUROPEAN UROLOGY FOCUS
卷 7, 期 1, 页码 47-54出版社
ELSEVIER
DOI: 10.1016/j.euf.2019.05.011
关键词
Active surveillance; Fusion biopsy; Multiparametric magnetic; resonance imaging; Prostate cancer
资金
- Yale School of Medicine
The study found that progression on serial mpMRI is not associated with pathological upgrade in men with GG1 PCa on active surveillance. However, a high initial PI-RADS score on mpMRI is predictive of subsequent pathological progression. Both systematic and fusion biopsies are necessary to monitor progression during active surveillance.
Background: Outcomes of serial multiparametric magnetic resonance imaging (mpMRI) and subsequent biopsy in monitoring prostate cancer (PCa) in men on active surveillance (AS) have not been defined clearly. Objective: To determine whether changes in serial mpMRI can predict pathological upgrade among men with grade group (GG) 1 PCa managed with AS. Design, setting, and participants: Retrospective analysis of men with GG1 on AS with at least two consecutive mpMRI examinations during 2012?2018 who underwent mpMRI/ ultrasound fusion or systematic biopsies. Outcome measurements and statistical analysis: Progression on serial mpMRI was eval-uated as a predictor of pathological upgrading to GG 2 on a follow-up biopsy using clinical, pathological, and imaging factors in binary logistic regression. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were determined. Results and limitations: Of 122 patients, 29 men (23.8%) experienced pathological upgrade on the follow-up biopsy. Progression on mpMRI was not associated with pathological upgrade. The sensitivity, specificity, PPV, and NPV of mpMRI progression for predicting pathological upgrade were 41.3%, 54.8%, 22.2%, and 75%, respectively. Age (odds ratio [OR] 1.17, p = 0.006), Prostate Imaging Reporting and Data System (PI-RADS) score on initial mpMRI (4?5 vs <3, OR 7.48, p = 0.01), number of positive systematic cores (OR 1.84, p = 0.03), number of positive targeted cores (OR 0.44, p = 0.04), and maximum percent of targeted core tumor involvement (OR 1.04, p = 0.01) were significantly associated with pathological upgrade. Conclusions: We did not observe an association between mpMRI progression and pathological upgrade; however, a PI-RADS score of 4?5 on initial mpMRI was predictive of subsequent pathological progression. The continued use of systematic and fusion biopsies appears necessary due to risks of reclassification over time. Patient summary: Progression on serial multiparametric magnetic resonance imaging during active surveillance (AS) is not associated with progression on the follow-up biopsy. Both systematic and fusion biopsies are necessary to sufficiently capture progression during AS. ? 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据